Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats

• Egile Nagusiak: Jong Mun Won (Egilea), Hyeon Gyeom Choi (Egilea), So Yeon Park (Egilea), Jang-Hee Kim (Egilea), So Hee Kim (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2023-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Tofacitinib, an inhibitor of Janus kinases (JAKs) 1 and 3, has been shown to be effective in the treatment of rheumatoid arthritis. The incidence of hyperlipidemia has been found to be higher in patients with rheumatoid arthritis. The present study therefore investigated the pharmacokinetics of tofa...